pubmed-article:18049729 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:18049729 | lifeskim:mentions | umls-concept:C0040077 | lld:lifeskim |
pubmed-article:18049729 | lifeskim:mentions | umls-concept:C0162675 | lld:lifeskim |
pubmed-article:18049729 | lifeskim:mentions | umls-concept:C0243071 | lld:lifeskim |
pubmed-article:18049729 | pubmed:issue | 47 | lld:pubmed |
pubmed-article:18049729 | pubmed:dateCreated | 2007-11-30 | lld:pubmed |
pubmed-article:18049729 | pubmed:abstractText | Neutron capture therapy (NCT) is a binary radio-chemotherapeutic modality for the treatment of cancer. A major focus of NCT-related research is the development of novel tumor-selective agents that serve as the chemical component in NCT. Thymidine analogues substituted with a boron-containing carborane cluster at the N3 position, designated 3CTAs (3-carboranyl thymidine analogues), constitute one class of these new improved NCT agents. Their chemical, structural and biological properties are discussed in this Feature Article. | lld:pubmed |
pubmed-article:18049729 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18049729 | pubmed:language | eng | lld:pubmed |
pubmed-article:18049729 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18049729 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:18049729 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18049729 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18049729 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18049729 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18049729 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:18049729 | pubmed:month | Dec | lld:pubmed |
pubmed-article:18049729 | pubmed:issn | 1359-7345 | lld:pubmed |
pubmed-article:18049729 | pubmed:author | pubmed-author:BarthRolf FRF | lld:pubmed |
pubmed-article:18049729 | pubmed:author | pubmed-author:TjarksWernerW | lld:pubmed |
pubmed-article:18049729 | pubmed:author | pubmed-author:ByunYoungjooY | lld:pubmed |
pubmed-article:18049729 | pubmed:author | pubmed-author:TiwariRohitR | lld:pubmed |
pubmed-article:18049729 | pubmed:author | pubmed-author:NarayanasamyS... | lld:pubmed |
pubmed-article:18049729 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:18049729 | pubmed:day | 21 | lld:pubmed |
pubmed-article:18049729 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:18049729 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:18049729 | pubmed:pagination | 4978-91 | lld:pubmed |
pubmed-article:18049729 | pubmed:meshHeading | pubmed-meshheading:18049729... | lld:pubmed |
pubmed-article:18049729 | pubmed:meshHeading | pubmed-meshheading:18049729... | lld:pubmed |
pubmed-article:18049729 | pubmed:meshHeading | pubmed-meshheading:18049729... | lld:pubmed |
pubmed-article:18049729 | pubmed:meshHeading | pubmed-meshheading:18049729... | lld:pubmed |
pubmed-article:18049729 | pubmed:meshHeading | pubmed-meshheading:18049729... | lld:pubmed |
pubmed-article:18049729 | pubmed:meshHeading | pubmed-meshheading:18049729... | lld:pubmed |
pubmed-article:18049729 | pubmed:meshHeading | pubmed-meshheading:18049729... | lld:pubmed |
pubmed-article:18049729 | pubmed:meshHeading | pubmed-meshheading:18049729... | lld:pubmed |
pubmed-article:18049729 | pubmed:year | 2007 | lld:pubmed |
pubmed-article:18049729 | pubmed:articleTitle | Carboranyl thymidine analogues for neutron capture therapy. | lld:pubmed |
pubmed-article:18049729 | pubmed:affiliation | College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA. tjarks.1@osu.edu | lld:pubmed |
pubmed-article:18049729 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:18049729 | pubmed:publicationType | Review | lld:pubmed |
pubmed-article:18049729 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
pubmed-article:18049729 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |